← FDA DRUG APPROVALS
FDA NDA · NDA021259
METHYLPHENIDATE HYDROCHLORIDE CD
methylphenidate hydrochloride
Sponsor: LANNETT
APPLICATION
NDA021259
TYPE
NDA
ORIGINAL APPROVAL
2001-04-03
LATEST ACTION
2025-09-23
ROUTE
ORAL
DOSAGE FORM
CAPSULE, EXTENDED RELEASE
MARKETING STATUS
Prescription
Products
METADATE CD · ReferencePrescription
METHYLPHENIDATE HYDROCHLORIDE 60MG · CAPSULE, EXTENDED RELEASE · ORAL
METADATE CD · ReferencePrescription
METHYLPHENIDATE HYDROCHLORIDE 40MG · CAPSULE, EXTENDED RELEASE · ORAL
METADATE CD · ReferencePrescription
METHYLPHENIDATE HYDROCHLORIDE 30MG · CAPSULE, EXTENDED RELEASE · ORAL
METADATE CD · ReferencePrescription
METHYLPHENIDATE HYDROCHLORIDE 50MG · CAPSULE, EXTENDED RELEASE · ORAL
METADATE CD · ReferencePrescription
METHYLPHENIDATE HYDROCHLORIDE 10MG · CAPSULE, EXTENDED RELEASE · ORAL
METADATE CD · ReferencePrescription
METHYLPHENIDATE HYDROCHLORIDE 20MG · CAPSULE, EXTENDED RELEASE · ORAL
Approval history
2015-06-15Manufacturing (CMC) · Supplement 28 · standardAP
2002-11-06Manufacturing (CMC) · Supplement 4 · standardAP
2002-11-06Manufacturing (CMC) · Supplement 3 · standardAP
2002-09-18Manufacturing (CMC) · Supplement 2 · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.